Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis.
Company profile
Website
CEO
Vlad Coric
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Biohaven Specialty Pharmaceutical Ltd. • Biohaven Therapeutics Ltd. • Biohaven Pharmaceuticals, Inc. • BioShin Limited • BioShin Hong Kong Limited • BioShin (Shanghai) Consulting Services Co., Limited • Biohaven Bioscience Ireland Limited • Biohaven Therapeutics IP Ltd. • Biohaven CGRP IP Ltd. • Biohaven Pharmaceutical Ireland ...
Latest filings (excl ownership)
15-12G
Securities registration termination
14 Oct 22
25-NSE
Exchange delisting
4 Oct 22
8-K
Termination of a Material Definitive Agreement
3 Oct 22
POSASR
Automatic shelf registration (post-effective amendment)
3 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Oct 22
8-K
Submission of Matters to a Vote of Security Holders
29 Sep 22
8-K
Regulation FD Disclosure
27 Sep 22
Transcripts
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 236.56 mm | 236.56 mm | 236.56 mm | 236.56 mm | 236.56 mm | 236.56 mm |
Cash burn (monthly) | (no burn) | 5.97 mm | 147.27 mm | 75.78 mm | (no burn) | 35.01 mm |
Cash used (since last report) | n/a | 130.33 mm | 3.22 bn | 1.66 bn | n/a | 764.88 mm |
Cash remaining | n/a | 106.22 mm | -2.98 bn | -1.42 bn | n/a | -528.32 mm |
Runway (months of cash) | n/a | 17.8 | -20.2 | -18.7 | n/a | -15.1 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 30.00 |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
FNY Investment Advisers | 0.00 | $0.00 |